MMWR Booster - Broadly Epi

MMWR Booster for: Disaggregating Data to Measure Racial Disparities in COVID-19 Outcomes and Guide Community Response — Hawaii, March 1, 2020–February 28, 2021 / September 17, 2021 / 70(37);1267–1273

Posted on December 22, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Disaggregated Data Reveals Disparities: Disaggregating COVID-19 data by specific racial subgroups in Hawaii highlighted significant disparities in case and mortality rates among Native Hawaiian, Pacific Islander, and

MMWR Booster for: Tobacco Product Use Among Adults — United States, 2020 / March 18, 2022 / 71(11);397–405

Posted on December 21, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Prevalence of Tobacco Use: In 2020, 19.0% of U.S. adults (47.1 million) used any tobacco product, with cigarettes being the most commonly used (12.5%). Decrease in Tobacco

MMWR Booster for: Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021 / September 24, 2021 / 70(38);1349–1354

Posted on December 21, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways High Attack Rate: 74% of incarcerated persons in two housing units were infected during the outbreak. Vaccination Impact: The attack rate was higher among unvaccinated persons (93%)

MMWR Booster for: Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 / September 24, 2021 / 70(38);1344–1348

Posted on December 20, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Full FDA Approval: The Pfizer-BioNTech COVID-19 vaccine, Comirnaty, received full FDA approval for use in persons aged ≥16 years on August 23, 2021. High Efficacy: Clinical trials

MMWR Booster for: Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022 / March 25, 2022 / 71(12);459–465

Posted on December 20, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways High Vaccine Effectiveness: Receiving 2 or 3 doses of an mRNA COVID-19 vaccine was associated with a 90% reduction in risk for COVID-19–associated invasive mechanical ventilation (IMV)

MMWR Booster for: COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022 / March 25, 2022 / 71(12);466–473

Posted on December 19, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Higher Hospitalization Rates During Omicron: Weekly COVID-19–associated hospitalization rates peaked at 38.4 per 100,000 adults during Omicron predominance, compared to 15.5 during Delta predominance. Impact of Vaccination

MMWR Booster for: Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 / September 24, 2021 / 70(38);1337–1343

Posted on December 19, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Higher VE for Moderna: The Moderna vaccine showed a higher vaccine effectiveness (VE) of 93% against COVID-19 hospitalizations compared to Pfizer-BioNTech’s 88% and Janssen’s 71%. Decline in

MMWR Booster for: Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 / April 1, 2022 / 71(13);495–502

Posted on December 18, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Vaccine Effectiveness (VE) Variability: VE against COVID-19–associated emergency department/urgent care visits was 24% after 1 Janssen dose, 54% after 2 Janssen doses, 79% after 1 Janssen/1 mRNA

MMWR Booster for: Decreased Incidence of Infections Caused by Pathogens Transmitted Commonly Through Food During the COVID-19 Pandemic — Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2017–2020 / September 24, 2021 / 70(38);1332–1336

Posted on December 18, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Significant Decrease in Infections: The incidence of infections caused by enteric pathogens decreased by 26% in 2020 compared to 2017–2019. Impact of COVID-19 Interventions: Public health measures

MMWR Booster for: Nonvoluntary or Forced Sex Among Women, by Sexual Identity, Attraction, and Behavior — National Survey of Family Growth, United States, 2011–2017 / September 24, 2021 / 70(38);1326–1331

Posted on December 17, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Higher Prevalence Among Sexual Minority Women: Sexual minority women, including those identifying as bisexual or lesbian, report significantly higher rates of nonvoluntary or forced sex compared to

Epidemiology, Broadly Speaking

Category: MMWR Booster